Core Viewpoint - LightPath Technologies, Inc. has announced a public offering of 7,750,000 shares of its Class A common stock at a price of $7.75 per share, aiming for gross proceeds of approximately $60 million before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,162,500 shares at the public offering price [1]. - The offering is expected to close on or about December 15, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, investments, acquisitions, and general corporate purposes [2]. Group 3: Underwriters - Canaccord Genuity and Craig-Hallum are serving as joint bookrunners for the offering, with Lake Street acting as co-manager [2]. Group 4: Company Overview - LightPath Technologies is a leading provider of next-generation optics and imaging systems for defense and commercial applications, with a vertically integrated approach and in-house engineering design support [5]. - The company’s manufacturing facilities are located in Orlando, Florida, with additional sites in Texas, New Hampshire, Latvia, and China [5].

Core Points - Terns Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 18,687,500 shares at a price of $40.00 per share, resulting in gross proceeds of $747.5 million before deductions [1][3] - The offering was managed by Jefferies, TD Cowen, and Leerink Partners as lead book-running managers, with Mizuho, Citizens Capital Markets, and Oppenheimer & Co. as co-managers [2] - The net proceeds from the offering will be utilized for research, clinical trials, development, and manufacturing of key product candidates, particularly TERN-701, as well as for working capital and general corporate purposes [3][5] Company Overview - Terns Pharmaceuticals is a clinical-stage oncology company focused on developing high-impact medicines, with its lead program TERN-701 being a selective allosteric BCR-ABL inhibitor aimed at improving treatment efficacy for chronic myeloid leukemia (CML) [5]

Core Viewpoint - Blink Charging Co. has announced a public offering of 26,666,666 shares at a price of $0.75 per share, aiming to raise approximately $20 million to fund capital expenditures and support working capital [1][3]. Group 1: Offering Details - The public offering is expected to close on or about December 12, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. and Roth Capital Partners are the exclusive co-placement agents for the offering [2]. - The gross proceeds from the offering are anticipated to be around $20 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used to expand the company's owned and operated DC Fast Charging network [3]. - Additional funds will support the company's working capital and general corporate requirements [3]. Group 3: Company Overview - Blink Charging Co. is a leader in electric vehicle charging equipment and services, facilitating the transition to electric transportation through innovative solutions [6]. - The company's offerings include EV charging networks, equipment, and services, utilizing proprietary cloud-based software for operation and maintenance [6]. - Blink Charging has established strategic partnerships for deploying charging solutions across various locations, including parking facilities, workplaces, and transportation hubs [6].

Hong Kong, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Top Wealth Group Holding Limited (NASDAQ: TWG)(“Top Wealth” or the “Company”), a leading supplier of premium-class sturgeon caviar and fine winery products, today announced the closing of a best-efforts public offering of 720,000 units (each a “Unit”), consisting of one Class A ordinary share of the Company, par value $0.009 per share (the “Class A Ordinary Shares”), one Series A Class A Warrant (the “Series A Class A Warrant”) and one Series B Class A Warrant (t ...

Core Viewpoint - Univest Securities, LLC has successfully closed a public offering for Top Wealth Group Holding Limited, raising approximately $5.04 million to support the company's operations in the premium caviar and fine winery products market [1][3]. Group 1: Offering Details - The offering consisted of 720,000 units, each unit comprising one Class A ordinary share and two types of warrants (Series A and Series B), priced at $7.00 per unit [2]. - The Class A warrants are immediately exercisable at an exercise price of $7.00 per share, with Series A warrants expiring five years after issuance and Series B warrants expiring eighteen months after issuance [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate and working capital purposes [3]. Group 3: Company Overview - Top Wealth Group Holding Limited is a Cayman Islands-based holding company, primarily operating through its subsidiary in Hong Kong, specializing in premium-class sturgeon caviar and winery products [6]. - The company’s caviar products are endorsed with CITES permits and are marketed under private labels as well as its own brand, "Imperial Cristal Caviar," which has seen significant sales growth since its launch [6]. Group 4: Univest Securities Overview - Univest Securities, LLC is a full-service investment bank and securities broker-dealer, registered with FINRA since 1994, providing a range of financial services globally [7]. - The firm has raised over $1.7 billion in capital for various issuers since 2019 and has completed around 100 transactions across multiple industries [7].

AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) (“T1,” “T1 Energy,” or the “Company”) today announced proposed underwritten public offerings of $120.0 million aggregate principal amount of its convertible senior notes due 2030 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $140.0 million of its shares of common stock (the “Common Stock Offering”). The Company intends to grant the underwriters a 30-day option to purchase up to an additional $18.0 ...

Core Viewpoint - Fulcrum Therapeutics, Inc. has announced a public offering of 11,851,853 shares of common stock priced at $13.50 per share, aiming to raise approximately $175 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 1,111,193 shares at a price of $13.499 per warrant, reflecting a slight discount from the common stock price [1]. - Fulcrum has granted underwriters a 30-day option to purchase an additional 1,944,456 shares under the same terms [1]. - The offering is expected to close around December 11, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for general corporate purposes, including working capital, capital expenditures, and research and development expenses [2]. - Specific allocations may include funding clinical trials, regulatory submissions, commercialization efforts, and potential acquisitions or investments in complementary technologies or assets [2]. Group 3: Company Background - Fulcrum Therapeutics is focused on developing small molecules for patients with genetically defined rare diseases, with its lead program targeting sickle cell disease through the modulation of gene expression [7].

Core Viewpoint - Dyne Therapeutics, Inc. has announced an upsized underwritten public offering of 18,980,478 shares at a price of $18.44 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of 18,980,478 shares of common stock priced at $18.44 each, with expected gross proceeds of $350 million [1]. - The offering is set to close on or about December 11, 2025, pending customary closing conditions [1]. - Dyne has granted underwriters a 30-day option to purchase an additional 2,847,071 shares at the public offering price [1]. Group 2: Underwriters - Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering [2]. Group 3: Regulatory Information - The offering is made under a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Group 4: Company Overview - Dyne Therapeutics focuses on improving the functionality of individuals with genetically driven neuromuscular diseases, developing therapeutics targeting muscle and the central nervous system [5]. - The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), along with preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5].

Core Viewpoint - Top Wealth Group Holding Limited has announced a public offering of 720,000 units at a price of $7.00 per unit, aiming to raise approximately $5.04 million before expenses [1][3]. Group 1: Offering Details - The offering consists of one Class A ordinary share and two types of warrants (Series A and Series B) [1]. - The Class A Warrants have an exercise price of $7.00 and are immediately exercisable, with Series A Warrants expiring in five years and Series B Warrants in eighteen months [1]. - The closing of the offering is expected around December 10, 2025, pending customary closing conditions [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are estimated at approximately $5.04 million, excluding placement agent fees and other expenses [3]. - If fully exercised, the Class A Warrants could generate an additional gross proceeds of about $10.08 million [3]. - The net proceeds will be used for general corporate and working capital purposes [3]. Group 3: Company Overview - Top Wealth Group Holding Limited is incorporated in the Cayman Islands and operates through its subsidiary in Hong Kong [6]. - The company specializes in premium-class sturgeon caviar and has a brand named "Imperial Cristal Caviar," which has seen significant sales growth since its launch [6]. - The caviar products are endorsed with CITES permits, allowing for legal international trade [6].

Core Viewpoint - Reed's, Inc. has successfully closed a public offering of 2,500,000 shares of common stock and warrants, aiming to enhance liquidity and visibility for shareholders while pursuing long-term profitability [1][3]. Group 1: Offering Details - The public offering included 2,500,000 shares of common stock and warrants, sold at a combined price of $4.00 per share [1]. - The warrants have an exercise price of $4.50 per share, are immediately exercisable, and will expire in five years [1]. - Gross proceeds from the offering are approximately $10 million, before deducting underwriting discounts and commissions [3]. Group 2: Stock Exchange Listing - Reed's common stock was approved for listing on the NYSE American and began trading on December 5, 2025, terminating its previous trading on the OTCQX Best Market [2]. Group 3: Management Commentary - The CEO of Reed's emphasized that the move to NYSE American reflects the company's commitment to growth and delivering value to shareholders [3]. Group 4: Company Background - Reed's, established in 1989, is a leader in craft beverages, offering high-quality, premium, better-for-you beverages under the Reed's®, Virgil's®, and Flying Cauldron® brand names, with products sold in over 32,000 stores nationwide [6]. Group 5: Underwriters - A.G.P./Alliance Global Partners acted as the sole book-running manager for the offering, with Roberts & Ryan, Inc. serving as a co-manager [4].